A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...

Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose regimen of nusinersen to advance the treatment of SMA CAMBRIDGE, Mass., Jan. 2 ...

Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational ... that the U.S. Food and Drug Administration (FDA) has accepted the ...

Halifax, Nova Scotia, 21st of January, 2025 - MedMira Inc. (MedMira) (TSXV: MIR) announced today that it has received Investigational Testing Authorizations (ITAs) from Health Canada to begin clinical ...

announced today that it has received Investigational Testing Authorizations (ITAs) from Health Canada to begin clinical trials for new label claim applications of its recently Health Canada ...

Raritan: Johnson & Johnson has announced it has initiated the submission of an original New Drug Application with the U.S. Food ... and no treatment-related deaths were reported. TAR-200 is an ...

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

The investigational drug, called PMD-026 ... “These patients have no effective medical therapies, so we hope this new drug will help fill that gap in clinical care. At minimum, we’re hopeful this drug ...

Please provide your email address to receive an email when new articles are posted on ... episodes and nighttime blood pressure (BP). The drug’s safety profile in this specific patient ...

Johnson & Johnson seeks FDA approval for TAR-200, targeting BCG-unresponsive high-risk NMIBC with CIS, through the Real-Time Oncology Review program. Phase 2b SunRISe-1 trial data showed an 83.5% ...